News

NemaGen Discoveries is thrilled to announce its acceptance into the 2025–2026 NYU Endless Frontier Labs (EFL) program. The EFL program is a highly competitive startup accelerator that partners world-class founders with leading investors, entrepreneurs, and scientists to advance breakthrough innovations from lab to market. Selection into this program recognizes NemaGen’s scientific potential and positions the company among a select group of ventures shaping the future of biotechnology.

NemaGen's President (Mark Siracusa) and CEO (Nick Shubin) will be attending the 2025 BIO International conference in Boston, June 16th-19th, 2025. We are currently setting meetings with potential investors and partners. If you plan on attending, please reach out to us for a meeting via the partnering portal or via email (nick.shubin@nemagen.com)! 

NemaGen's President (Mark Siracusa) and CEO (Nick Shubin) will be attending and presenting at the BIONJ-partnering conference at the Liberty Science Center, May 13th, 2025. If you plan on attending, please reach out to us for a meeting!

NemaGen is thrilled to announce that we were granted an Innovation and Research Fellowship Program (IRFP) award from the New Jersey Department of Labor and Workforce Development (NJ-DOL). This award provides salary support for a NemaGen postdoc to help advance our drug development programs. We would like to thank the NJ-DOL for tremendous support!

NemaGen is thrilled to announce that we were granted an Innovation and Research Fellowship Program (IRFP) award from the New Jersey Department of Labor and Workforce Development (NJ-DOL). This award provides salary support for a NemaGen postdoc to help advance our drug development programs. We would like to thank the NJ-DOL for tremendous support!

NemaGen is thrilled to announce that we were granted an Innovation and Research Fellowship Program (IRFP) award from the New Jersey Department of Labor and Workforce Development (NJ-DOL). This award provides salary support for a NemaGen postdoc to help advance our drug development programs. We would like to thank the NJ-DOL for tremendous support!

in 2024, NemaGen received multiple grants from the New Jersey Economic Development Authority, CSIT, including a phase I SBIR bridge grant, a phase II SBIR bridge grant, and a catalyst voucher award that allowed us to conduct studies with NJ-based core facilities. We are thrilled to have received these awards, and are very grateful to NJEDA-CSIT for their support!

To further support our drug development, NemaGen participated in an NIH I-Corps Program March-April 2023 to speak with various stakeholders to better understand their needs and validate our therapy's value.  This program also comes with a $55,000 grant award. Thanks to NCATS for further supporting our efforts to develop therapies treating mastocytosis and other mast cell-related diseases!

NemaGen is honored and excited to announce that we were awarded an NIH Small Business Innovation Research grant. We would like to thank the NIH and NCATS for recognizing the significance and impact of our work focused on treating mastocytosis and other mast cell-related diseases.

Dr. Mark Siracusa spoke at the 24th conference which took place from October 13-20th, 2021

The 25th conference will take place in October 2022

NemaGen's exciting findings have defined a previously unappreciated neuropeptide pathway that prevents unwanted lung inflammation. These studies were recently published in Nature Immunology.

The Foundation Venture Capital Group has recently invested $1MM towards the development of NemaGen's technologies